•
Mar 31, 2021
Kodiak Sciences Q1 2021 Earnings Report
Reported financial results for the first quarter ended March 31, 2021.
Key Takeaways
Kodiak Sciences reported a net loss of $50.4 million for the first quarter of 2021, with R&D expenses increasing to $40.3 million due to higher clinical trial costs for KSI-301. The company ended the quarter with $929.0 million in cash, cash equivalents, and marketable securities.
DAZZLE study is fully enrolled.
RVO and DME pivotal studies are all recruiting globally.
DAYLIGHT study will evaluate monthly dosing of KSI-301 in patients with wet AMD.
Construction of the manufacturing facilities is now targeted for completion in early 2022.